Relay Therapeutics, Inc. (RLAY) stock
RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$16.47−0.80 (-4.63%)
Close on Nov 17, 2026Market cap $3.61BP/E –Yield –
Relay Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Relay Therapeutics's price to sales ratio was 416.4× on Nov 11, 2026, against 163.6× a year earlier. Over the last 2 years it ranged from 37.8× to 416.4×, with a median of 116.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 416.4× | +241.6 |
| 2025 | Dec 31, 2025 | 174.8× | +130.6 |
| 2024 | Jan 31, 2024 | 44.2× | −8.4 |
| 2023 | Dec 29, 2023 | 52.6× | – |
See a number that looks wrong?